IP Library › Granted Patent US 7,598,234
Granted Patent B2
US 7,598,234 · App. 10/892,828 · Granted Oct 6, 2009

Steroid derived antibiotics

Assignee: Brigham Young University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,598,234
App. No.
10/892,828
Granted
Oct 6, 2009
Kind
B2
Abstract

A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.

Claims (53)

1. A method of treating a microbial infection of a host by administering to the host an effective amount of an anti-microbial composition comprising a compound according to formula I

wherein:

fused rings A, B, C, and D are independently saturated or fully or partially unsaturated; and R 1 through R 4 , R 6 , R 7 , R 11 , R 12 , R 15 , R 16 , and R 17 is each independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted arylamino-(C1-C10) alkyl, (C1-C10) haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, (C1-C10) quaternaryammoniumalkylcarboxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and

R 5 , R 8 , R 9 , R 10 , R 13 , and R 14 is each independently:

deleted when one of fused rings A, B, C, or D is unsaturated so as to complete the valency of the carbon atom at that site, or

selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, C1-C10 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and

provided that at least two of R 1 through R 14 are independently selected from the group consisting of a substituted or unsubstituted (C1-C10) aminoalkyloxy, (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted arylamino-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, (C1-C10) quaternaryammonium alkylcarboxy, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein at least one of the following pairs is deleted and the valency of the ring carbon atoms at these deleted positions is completed with a double bond: R 5 and R 9 ; R 8 and R 10 ; and R 13 and R 14 .

3. The method of claim 1 , wherein at least three of R 1 through R 14 are independently selected from the group consisting of a substituted or unsubstituted (C1-C10) aminoalkyloxy, (C1-C10) alkylcarboxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, a substituted or unsubstituted arylamino-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, (C1-C10) quaternaryammoniumalkylcarboxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy.

4. The method of claim 3 , wherein the 3 of R 1 through R 14 independently selected from the group consisting of a substituted or unsubstituted (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted arylamino-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, and (C1-C10) quaternaryammoniumalkylcarboxy.

5. The method of claim 1 , wherein the second steroid is a compound of formula I.

6. The method of claim 1 , wherein the linking group is (C1-C10) alkyl-oxy-(C1-C10) alkyl.

7. The method of claim 1 , wherein none of R 5 , R 8 , R 9 , R 13 , and R 14 is deleted.

8. The method of claim 1 , wherein each of R 3 , R 7 , and R 12 is independently selected from the group consisting of a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkylcarboxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 8 , R 10 , R 11 , R 13 , R 14 , R 15 and R 16 are hydrogen.

10. The method of claim 9 , wherein R 17 is —CR 18 R 19 R 20 , where each of R 18 , R 19 , and R 20 , is independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, (C1-C10) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, oxo, and a linking group attached to a second steroid.

11. The method of claim 8 , wherein each of R 3 , R 7 , and R 12 , is independently selected from the group consisting of —O—(CH2)n-NH2, —O—CO—(CH2)n-NH2, —O—(CH2)n-NH—C(NH)—NH2, —O—(CH2)n-N3, —O—(CH2)n-CN, where n is 1 to 3, and —O—C(O)—HC(Q5)-NH2, where Q5 is a side chain of any amino acid.

12. The method of claim 8 , wherein each of R 3 , R 7 , and R 12 , is —O—CO—(CH2)n-NH2, where n is 1 to 4.

13. The method of claim 12 , wherein R17 is —CH(CH 3 )(CH 2 ) 3 —O—(CH 2 ) n —NH 2 , wherein n is 1-7.

14. The method of claim 12 , wherein R17 is —CH(CH 3 )—(CH 2 ) n —NR 1 R 2 , wherein n is 0-2, R 1 and R 2 are independently (C1-C6) alkyl, aryl or aralkyl.

15. The method of claim 1 , wherein R17 is —CH(CH 3 )(CH 2 ) n1 —CO—OR 3 , where R 3 is selected from —(CH 2 ) n2 N + (CH 3 ) 3 , wherein n1 and n2 are independently 1-4.

16. The method of claim 15 , wherein R3, R7, and R12 are —O—C(O)—(CH 2 ) n —NH 2 , wherein n is 1-5.

17. The method of claim 1 having the following formula:

wherein n is 1-3, and Bn is a benzyl group.

18. The method of claim 1 having the following formula:

wherein n is 1-3, and R is selected from n-octyl, and trimethylethylammonio.

19. The method of claim 1 having the formula:

20. The method of claim 1 wherein the compound has the formula:

wherein R 1 is selected from hydrogen, or (C1-C10) alkylamino, R 2 is selected from (C1-C10) alkylamino or (C1-C10) alkylamino-(C1-C10) alkylamino, and n is 1-3.

21. The method of claim 1 , wherein R 1 is hydrogen and R 2 is (C1-C10) alkylamino-(C1-C10) alkylamino.

22. The method of claim 1 , wherein R 1 is (C1-C10) alkylamino, and R 2 is (C1-C10) alkylamino.

23. The method of claim 1 , wherein the compound has the following formula:

wherein:

fused rings A, B, C, and D are independently saturated or fully or partially unsaturated; and R 1 through R 4 , R 6 , R 7 , R 11 , R 12 , R 15 , and R 16 , is each independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted arylamino-(C1-C10) alkyl, (C1-C10) haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, (C1-C10) quaternaryammoniumalkylcarboxy, and (C1-C10 guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and

R 5 , R 8 , R 9 , R 10 , R 13 , and R 14 is each independently:

deleted when one of fused rings A, B, C, or D is unsaturated so as to complete the valency of the carbon atom at that site, or

selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, C1-C10 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and

R 17 is selected from the group consisting of substituted or unsubstituted alkylcarboxyalkyl and protected or unprotected poly(aminoalkyl),

provided that at least two of R 1 through R 14 are independently, selected from the group consisting of a substituted or unsubstituted (C1-C10) aminoalkyloxy, (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted arylamino-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, (C1-C10) quaternaryammonium alkylcarboxy, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy; or a pharmaceutically acceptable salt thereof.

24. The compound of claim 23 , wherein the compound has the formula:

wherein n is 1-3.

25. The method of claim 23 , wherein the compound has the formula:

wherein n is 1-3.

26. The method of claim 23 , wherein the compound has the formula:

27. The method of claim 23 , wherein the compound has the formula:

28. The method of claim 23 , wherein the compound has the formula:

29. The method of claim 1 , wherein R12 is selected from the group consisting of hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, (C1-C10) alkylcarboxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkylamino, (C1-C10) alkylamino-(C1-C10) alkylamino-(C1-C10) alkylamino, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted arylamino-(C1-C10) alkyl, (C1-C10) haloalkyl, C2-C6-alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkyloxy(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2N—HC(Q5)-C(O)—O—, H2N—HC(Q5)-C(O)—N(H)—, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN—HC(Q5)-C(O)—O—, (C1-C10) guanidinoalkyloxy, (C1-C10) quaternaryammoniumalkylcarboxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group.

30. The method of claim 1 wherein the host is a human.

31. The method of claim 1 wherein the anti-microbial composition further comprises a second anti-microbial substance to be delivered into a microbial cell.

32. The method of claim 31 wherein the second anti-microbial substance is an antibiotic.

33. The method of claim 1 wherein the infection is a bacterial infection.

34. The method of claim 33 wherein the infection is a infection a Gram-negative bacterial infection.

35. The method of claim 33 wherein the bacterial infection is an infection with a bacterium characterized by an outer membrane comprising a substantial percentage of lipid A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2008
From: SAVAGE, PAUL B.; LI, CHUNHONG
To: BRIGHAM YOUNG UNIVERSITY
Reel/Frame 021984/0451 →
Continuity (5)
Continuation 0993031600 · Aug 15, 2001
Continuation In Part 0923400800 · Jan 19, 1999
Continuation In Part PCTUS980448900 · Mar 6, 1998
Provisional Application 6022546700 · Aug 15, 2000
Related Publication 20050032765A1 · Feb 10, 2005